Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0923 7534 "

Sökning: L773:0923 7534

Sortera/gruppera träfflistan
  • Li, Jingmei, et al. (författare)
  • Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers
  • 2015
  • Ingår i: Annals of Oncology. - Stockholm : Karolinska Institutet, Dept of Medical Epidemiology and Biostatistics. - 0923-7534. ; 26:3, s. 517-522
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Polygenic risk profiles computed from multiple common susceptibility alleles for breast cancer have been shown to identify women at different levels of breast cancer risk. We evaluated whether this genetic risk stratification can also be applied to discriminate between screen-detected and interval cancers, which are usually associated with clinicopathological and survival differences. Patients and methods: A 77-SNP polygenic risk score (PRS) was constructed for breast cancer overall and by estrogen-receptor (ER) status. PRS was inspected as a continuous (per standard deviation increment) variable in a case-only design. Modification of the PRS by mammographic density was evaluated by fitting an additional interaction term. Results: PRS weighted by breast cancer overall estimates was found to be differentially associated with 1,865 screen-detected and 782 interval cancers in the LIBRO-1 study (age-adjusted ORperSD [95% confidence interval]=0.91 [0.83-0.99], p=0.023). The association was found to be more significant for PRS weighted by ER-positive breast cancer estimates (ORperSD=0.90 [0.82-0.98], p=0.011). This result was corroborated by two independent studies (combined ORperSD=0.87 [0.76-1.00], p=0.058) with no evidence of heterogeneity. When enriched for “true” interval cancers among nondense breasts, the difference in the association with PRS in screen-detected and interval cancers became more pronounced (ORperSD=0.74 [0.62-0.89], p=0.001), with a significant interaction effect between PRS and mammographic density (pinteraction=0.017). Conclusion: To our knowledge, this is the first report looking into the genetic differences between screendetected and interval cancers. It is an affirmation that the two types of breast cancer may have unique underlying biology.
  • Aaltonen, K. E., et al. (författare)
  • Gene expression of breast cancer related genes in circulating tumour cells (CTCs) from patients with metastatic breast cancer
  • 2015
  • Ingår i: Annals of Oncology. - : Oxford University Press. - 0923-7534. ; 26:Suppl. 3, s. 15-15
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: Detection of circulating tumour cells (CTCs) in peripheral blood has an established prognostic significance in patients with metastatic breast cancer. Change in the number of detected CTCs is also an indication of response to therapy. Characterisation of CTCs could provide easily accessible treatment predictive information of present cancer cells within the patient and could reveal important knowledge about the metastatic process. The aim of this pilot study was to characterize CTCs with regard to both treatment predictive and more experimental markers by analysing the expression of genes associated with breast cancer.Methods: Blood samples from twelve patients with metastatic breast cancer included in the ongoing CTC-MBC study at Lund University, Sweden (Clinical Trials Id. NCT01322893) were analysed in this pilot study. Systemic treatment included endocrine, targeted and chemotherapy regimen. Blood samples were collected before start of 1st line therapy and at four time points. If progression occurred, a new round of samples was taken. CTCs were isolated from whole blood using the commercial kits AdnaTest EMT1/stem cell and AdnaTest EMT2/stem cell (AdnaGen AG, Langenhagen, Germany). With this method, CTCs are captured using antibodies directed against EpCAM and MUC-1 (EMT1-kit) or EpCAM, HER2 and EGFR (EMT2-kit). Gene expression analyses from CTCs at each time point was performed by TATAA Biocenter (Gothenburg, Sweden) using qPCR. 38 breast cancer related genes were analysed including the oestrogen receptor (ESR), HER2, VEGFR2, ALDH1, PI3K, PTEN and TWIST1.Results: Using positive expression of pseudo-markers EpCAM, MUC1 and HER2 as definition of CTCs, 6 of 12 patients were positive for CTCs. However, gene expression of additional markers in potential CTCs suggests complex patterns such as an increase in TWIST1, ALDH1 and SATB1 at time of progression.Conclusions: We present gene expression data from CTCs isolated before and during therapy in metastatic breast cancer patients. This type of characterisation could provide information of importance for treatment response and clinical outcome.Clinical trial identification: NCT01322893, March 24 2011
  • Aebi, S, et al. (författare)
  • Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
  • 2011
  • Ingår i: ANNALS OF ONCOLOGY. - 0923-7534. ; 22:9, s. 1981-1987
  • Tidskriftsartikel (refereegranskat)abstract
    • Abstract: Background: The benefit of adjuvant chemotherapy in postmenopausal patients with estrogen receptor (ER)positive lymph node-negative breast cancer is being reassessed. Patients and methods: After stratification by ER status, 1669 postmenopausal patients with operable lymph nodenegative breast cancer were randomly assigned to three 28-day courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy followed by tamoxifen for 57 months (CMF/tamoxifen) or to tamoxifen alone for 5 years. Results: ERs were positive in 81% of tumors. At a median follow-up of 13.1 years, patients with ER-positive breast cancers did not benefit from CMF [13-year disease-free survival (DFS) 64% CMF/tamoxifen, 66% tamoxifen; P = 0.99], whereas CMF substantially improved the prognosis of patients with ER-negative breast cancer (13-year DFS 73% versus 57%, P = 0.001). Similarly, breast cancer-free interval (BCFI) was identical in the ER-positive cohort but significantly improved by chemotherapy in the ER-negative cohort (13-year BCFI 80% versus 63%, P = 0.001). CMF had no influence on second nonbreast malignancies or deaths from other causes. Conclusion: CMF is not beneficial in postmenopausal patients with node-negative ER-positive breast cancer but is highly effective within the ER-negative cohort. In the future, other markers of chemotherapy response may define a subset of patients with ER-positive tumors who may benefit from adjuvant chemotherapy.
  • Ahlstedt Karlsson, Susanne, et al. (författare)
  • Experiences of endocrine therapy after breast cancer surgery
  • 2019
  • Ingår i: Annals of Oncology. Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain. Vol. 30, Suppl. 5, s. v840. - 0923-7534.
  • Konferensbidrag (refereegranskat)abstract
    • Background For patients diagnosed with hormone-receptor-positive breast cancer, endocrine therapy (ET) is prescribed, which reduces recurrence and mortality rates (Early Breast Cancer Trialists’ Collaborative Group, 2011). Despite the prognostic benefits of ET, the adherence to treatment varies, and 30%–70% of the patients discontinue their treatment within five years (Daly et al., 2017; Tinari et al., 2015; Ursem et al., 2015), often during their first year of treatment (He et al., 2015), due to the fact that ET is associated with adverse side-effects (Regan et al., 2011). Methods The study was conducted in a surgical out-patient care unit at a hospital in Sweden. Inclusion criteria were women diagnosed with breast cancer and treated with ET after surgery. Forty-eight patients were invited to participate, of which 23 declined, thus 25 women were included. Seven focus group interviews, with two to five participants in each group, were conducted using an interview guide according to Krueger’s (2014) strategy. The interview guide contained six open-ended questions aiming to explore the women’s experiences of ET after breast cancer surgery. Inductive qualitative content analysis was used (Graneheim & Lundman, 2004). Results The analysis resulted in three categories that described the women’s experiences: the treatment “creates discomfort”; “promotes levels of management”; and “causes feelings of abandonment”. Women’s experiences of treatment could at first glance be seen as positive, as perceived protection, but after further analysis, a deeper meaning was identified: protection with reservation. When experiencing discomfort, the women were urged to manage the situation, although the mode of management sometimes varied. The women reported that they needed support, but when the support did not appear, they felt as though they had been abandoned. Moreover, knowledge about side-effects became an obstacle. The participants described feeling abandoned, but they also described their disease as “cancer light”. Conclusions Professionals need to explore the pre-knowledge and preconceptions that patients might have. This could be achieved by listening to the patient before providing them with information. The information needs to be customized specifically to each person. Funding Assar Gabrielsson’s Foundation, Herbert and Karin Jacobsson’s Foundation, and the Swedish Society of Nursing. Disclosure All authors have declared no conflicts of interest.
  • Alkner, S, et al. (författare)
  • AIB1 is a predictive factor for tamoxifen response in premenopausal women
  • 2010
  • Ingår i: ANNALS OF ONCOLOGY. - : Oxford University Press. - 0923-7534. ; 21, s. 238-244
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Clinical trials implicate the estrogen receptor ( ER) coactivator amplified in breast cancer 1 (AIB1) to be a prognostic and a treatment-predictive factor, although results are not unanimous. We have further investigated this using a controlled randomised trial of tamoxifen versus control. Materials and methods: A total of 564 premenopausal women were entered into a randomised study independent of ER status. Using a tissue microarray, AIB1 and ER were analysed by immunohistochemistry. Results: AIB1 scores were obtained from 349 women. High AIB1 correlated to factors of worse prognosis (human epidermal growth factor receptor 2, Nottingham histological grade 3, and lymph node metastases) and to ER negativity. In the control arm, high AIB1 was a negative prognostic factor for recurrence- free survival (RFS) (P = 0.02). However, ER-positive patients with high AIB1 responded significantly to tamoxifen treatment (P = 0.002), increasing RFS to the same level as for systemically untreated patients with low AIB1. Although ER-positive patients with low AIB1 had a better RFS from the beginning, this was not further improved by tamoxifen (P = 0.8). Conclusions: In the control group, high AIB1 was a negative prognostic factor. However, ER-positive patients with high AIB1 responded significantly to tamoxifen. This implicates high AIB1 to be an independent predictive factor of improved response to tamoxifen and not, as has previously been discussed, a factor predicting tamoxifen resistance.
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (292)
konferensbidrag (192)
forskningsöversikt (13)
Typ av innehåll
övrigt vetenskapligt (253)
refereegranskat (242)
populärvet., debatt m.m. (2)
Glimelius, B (51)
Bergh, J (45)
Glimelius, Bengt (39)
Mellstedt, H (33)
Öberg, Kjell (21)
Berglund, A. (19)
visa fler...
Sorbye, H. (17)
Tumino, R. (16)
Riboli, E. (16)
Osterborg, A (15)
Cervantes, A (15)
Kaaks, R. (14)
Palli, D (14)
Jonsson, B (13)
Hatschek, T (13)
Hansson, J. (13)
Trichopoulou, A (13)
Bjorkholm, M (13)
Weiderpass, E (12)
Overvad, K (12)
Tjonneland, A (12)
Boeing, H. (12)
Quiros, J. R. (12)
Eriksson, M (12)
Wolk, A (12)
Lehtio, J (12)
Bueno-de-Mesquita, H ... (11)
Cunningham, D (11)
Vineis, P (11)
Panico, S (11)
Berglund, Åke (11)
Barricarte, A (10)
Ostman, A (10)
Bystrom, P (10)
Liu, T. (9)
Khaw, K. T. (9)
Jenab, M (9)
Sánchez, M-J (9)
Peeters, P H (9)
Ferrari, P. (8)
Pavel, M (8)
Amiano, P. (8)
Kokhaei, P (8)
Choudhury, A (8)
Czene, K (8)
Bamia, C (8)
Sund, M (8)
Racine, A (8)
Haustermans, K. (8)
Vergote, I. (8)
visa färre...
Karolinska Institutet (321)
Uppsala universitet (120)
Umeå universitet (43)
Lunds universitet (33)
Linköpings universitet (32)
Göteborgs universitet (23)
visa fler...
Örebro universitet (11)
Kungliga Tekniska Högskolan (3)
Stockholms universitet (2)
Jönköping University (2)
Ersta Sköndal Bräcke högskola (2)
Mälardalens högskola (1)
Mittuniversitetet (1)
Högskolan i Skövde (1)
Chalmers tekniska högskola (1)
RISE (1)
Karlstads universitet (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Engelska (497)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (157)
Naturvetenskap (3)
Samhällsvetenskap (2)
Teknik (1)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy